The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

Waldenström’s macroglobulinemia (WM) remains an incurable malignancy. However, a number of treatment options exist for patients with WM, including alkylating agents, anti-CD20 monoclonal antibodies, and small molecule inhibitors such as proteasome inhibitors and Bruton tyrosine kinase inhibitors (BT...

Descripción completa

Detalles Bibliográficos
Autor principal: Khan, Abdullah Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146645/
https://www.ncbi.nlm.nih.gov/pubmed/35629099
http://dx.doi.org/10.3390/jpm12050676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146645/
https://www.ncbi.nlm.nih.gov/pubmed/35629099
http://dx.doi.org/10.3390/jpm12050676

Ejemplares similares